AG
MLYS icon

Algert Global’s Mineralys Therapeutics MLYS Stock Holding History

Algert Global’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Buy
649,027
+388,763
+149% +$10.7M 0.21% 112
2026
Q1 		$7.05M Buy
260,264
+212,764
+448% +$6.24M 0.11% 332
2025
Q4 		$1.72M Hold
47,500
– – 0.03% 743
2025
Q3 		$1.8M Buy
+47,500
New +$1.03M 0.03% 709
2024
Q4 		– Sell
-11,196
Closed -$136K – 1268
2024
Q3 		$136K Buy
+11,196
New +$136K ﹤0.01% 1093

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Algert Global's MLYS Position: Q2 2026 in Review

Algert Global increased its Mineralys Therapeutics (MLYS) stake by 149% in Q2 2026, buying an estimated $10.7M and bringing the position to 649,027 shares worth $17.5M. The position accounts for 0.21% of the portfolio, ranked #112.

Algert Global first reported a position in MLYS in Q3 2024 and has held it in 5 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Algert Global held 649,027 shares of Mineralys Therapeutics worth $17.5M as of Q2 2026.
  • Algert Global bought 388,763 Mineralys Therapeutics shares in Q2 2026, an estimated $10.7M.
  • Mineralys Therapeutics made up 0.21% of Algert Global's portfolio in Q2 2026, its #112 holding.
  • Algert Global first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.